Hepatic artery-infusion chemotherapy improved survival of hepatocellular carcinoma after radical hepatectomy
Authors Feng M, Tang C, Feng W, Bao Y, Zheng Y, Shen J
Received 12 March 2017
Accepted for publication 17 May 2017
Published 14 June 2017 Volume 2017:10 Pages 3001—3005
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 3
Editor who approved publication: Dr William Cho
Min Feng,1 Chengwu Tang,1 Wenming Feng,1 Ying Bao,1 Yinyuan Zheng,2 Jianbin Shen1
1Department of General Surgery, 2Department of Radiology, First People’s Hospital, Huzhou University Medical College, Huzhou, Zhejiang, China
Objective: To evaluate the effect of postoperative hepatic artery-infusion chemotherapy (HAIC) on survival probability in patients with hepatocellular carcinoma (HCC) after radical hepatectomy.
Patients and methods: This retrospective study included 85 patients with HCC who received radical hepatectomy from May 2005 to May 2010. Among these patients, 42 underwent two sessions of HAIC (5-fluoruracil [1,000 mg/m2], oxaliplatin [85 mg/m2], and mitomycin-C [6 mg/m2]) after radical hepatectomy (HAIC group), and 43 underwent radical hepatectomy only (the control group). HAIC-related side effects and long-term survival were retrospectively analyzed.
Results: The HAIC group showed a significantly higher 5-year intrahepatic recurrence-free survival probability and lower risk of intrahepatic recurrence (HR 0.5615, 95% CI 0.3234–0.9749 [log-rank test]; P=0.0332). The HAIC group also had significantly higher 5-year disease-free survival probability (HR 0.591, 95% CI 0.3613–0.9666 [log-rank test]; P=0.0298) and overall survival probability than the control group (HR 0.5768, 95% CI 0.3469–0.9589 [log-rank test]; P=0.0278). No HAIC-related deaths in the HAIC group were reported. All toxicities and complications were controlled, and no patients quit the treatment.
Conclusion: HAIC can effectively and safely reduce intrahepatic recurrence and improve the long-term survival of patients with HCC after radical hepatectomy.
Keywords: hepatocellular carcinoma, hepatic artery-infusion chemotherapy, intrahepatic recurrence, metastasis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]